Last checked at 31 Jul 2017 07:00
Physiomics plc
("Physiomics") or ("the Company")
Two new pre-clinical contracts
Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it has today signed two new contracts with a global pharma company for Virtual Tumour pre-clinical predictions relating to a new oncology target. This marks the sixth year of collaboration with this company since a first pre-clinical project was announced in March 2012.
The two contracts will be executed in parallel between now and the end of the calendar year.
Jim Millen, CEO said: "We are delighted by these new contracts which we believe are a sign of the client's long-term commitment to Physiomics and its Virtual Tumour technology. We look forward to continuing to work closely with them going forwards".
This announcement refers to a contract in the ordinary course of business for Physiomics.
Enquiries:
Physiomics plc
Dr Jim Millen, CEO
+44 (0)1865 784 980
WH Ireland Limited (nomad)
Katy Mitchell
+44 (0) 161 832 2174
Hybridan LLP (broker)
Claire Louise Noyce
+44 (0) 203 764 2341